HOSPITAL UNIVERSITARIO RUBER
Departamento
University of California Los Angeles
Los Ángeles, Estados UnidosPublicaciones en colaboración con investigadores/as de University of California Los Angeles (7)
2020
-
Trastuzumab deruxtecan in previously treated HER2-positive breast cancer
New England Journal of Medicine, Vol. 382, Núm. 7, pp. 610-621
2017
-
Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial
The Lancet Oncology, Vol. 18, Núm. 7, pp. 904-916
-
The Polyanalgesic Consensus Conference (PACC): Recommendations for Intrathecal Drug Delivery: Guidance for Improving Safety and Mitigating Risks
Neuromodulation, Vol. 20, Núm. 2, pp. 155-176
2016
-
Afatinib plus vinorelbine versus trastuzumab plus vinorelbine in patients with HER2-overexpressing metastatic breast cancer who had progressed on one previous trastuzumab treatment (LUX-Breast 1): An open-label, randomised, phase 3 trial
The Lancet Oncology, Vol. 17, Núm. 3, pp. 357-366
-
HERMIONE: A randomized Phase 2 trial of MM-302 plus trastuzumab versus chemotherapy of physician's choice plus trastuzumab in patients with previously treated, anthracycline-naïve, HER2-positive, locally advanced/metastatic breast cancer
BMC Cancer, Vol. 16, Núm. 1
2015
-
Afatinib alone or afatinib plus vinorelbine versus investigator's choice of treatment for HER2-positive breast cancer with progressive brain metastases after trastuzumab, lapatinib, or both (LUX-Breast 3): A randomised, open-label, multicentre, phase 2 trial
The Lancet Oncology, Vol. 16, Núm. 16, pp. 1700-1710